charlotte17 Posted May 10, 2017 Share Posted May 10, 2017 Does anyone know of any challenges related to clinic trial of pharmacotherapies particular in phase 2 and 3? I have bio - availability, plasma half-life, compliance and side effects. Not sure which would fit where though. Link to comment Share on other sites More sharing options...
Function Posted May 10, 2017 Share Posted May 10, 2017 Compliance seems rather a challenge of phase 3 and 4 studies; to a lesser degree phase 2. Bioavailability, plasma half-life would seem phase 2 to me, and side-effects actually phase 1 or 2: some side-effects may already be observed in a preclinical phase in laboratory animals. Efficacy is typically phase 3, whereas efficiency (cost-effectiveness) applies to phase 4 studies ... Of course, the degree to which you may or may not extrapolate your results is a huge problem in phase 2 and 3 studies. Link to comment Share on other sites More sharing options...
Recommended Posts
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now